News & Events

shall be deemed to be furnished and not filed: 99.1 Press release of Centene Corporation issued April 28, 2026, as to financial results for the first quarter ended March 31, 2026. EXHIBIT INDEX Exhibit Number Description 99.1* Press release of Centene Corporation issued April 28, 2026 as to financial results for the first quarter ended March 31, 2026 104 Cover page information from Centene Corporation’s Current Report on Form 8-K filed on April 28, 2026 formatted in Inline Extensible Business…

DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS Effective March 18, 2026, the Board of Directors (the Board) of Centene Corporation (the Company) appointed Theodore Pienkos, 44, a registered CPA, to serve as the Company's Corporate Controller and Chief Accounting Officer. Mr. Pienkos previously has served as the Company's Deputy Corporate Controller since August 2024. Prior to that, he served as…

OTHER EVENTS On March 10, 2026, the Company delivered a notice of partial redemption to redeem on March 25, 2026 (the redemption date) $1,000,000,000 aggregate principal amount of its outstanding 4.25% Notes due December 15, 2027 (the 2027 Notes) in accordance with the terms of the 2027 Notes and the Indenture dated as of December 6, 2019 between the Company and The Bank of New York Mellon Trust Company, N.A. as trustee. Following the redemption, approximately $1,186,664,000 of the 2027 Notes…

REGULATION FD DISCLOSURE Centene Corporation (the Company) will be presenting at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026, at 8:30 a.m. EDT. A simultaneous live audio webcast of the presentation on March 10 will be available at https://event.webcasts.com/starthere.jsp?ei=1753406&tp_key=d357b0a0a7&tp_special=8. A webcast replay will be available following the presentation via the Company's website at www.centene.com, under the Investors section. During t…

REGULATION FD DISCLOSURE Members of Centene Corporation's (the Company's) senior management team will meet with investors the week of February 23, 2026. Consistent with the Company's guidance previously provided on February 6, 2026, the senior management team plans to reaffirm the Company's 2026 full year GAAP diluted earnings per share (EPS) guidance of greater than $1.98 and its full year adjusted diluted EPS guidance of greater than $3.00. Non-GAAP Financial Presentation The Company is pro…

shall be deemed to be furnished and not filed: 99.1 Press release of Centene Corporation issued February 6, 2026, as to financial results for the fourth quarter and year ended December 31, 2025 99.2 Centene Corporation 2026 Guidance Presentation EXHIBIT INDEX Exhibit Number Description 99.1* Press release of Centene Corporation issued February 6, 2026 as to financial results for the fourth quarter and year ended December 31, 2025 99.2* Centene Corporation 2026 Guidance Presentation 104 Cover…

REGULATION FD DISCLOSURE Centene Corporation (the Company) will appear at the UBS 2025 Global Healthcare Conference on Tuesday, November 11, 2025, at 10:15 a.m. EST. At the conference, and in subsequent discussions with investors, members of management will discuss the Company's financial outlook, which is consistent with its previously-issued full year 2025 GAAP forecast of a diluted loss per share not to exceed $(12.85) and full year 2025 adjusted diluted earnings per share (EPS) forecast o…

REGULATION FD DISCLOSURE Centene Corporation (the Company) will be participating at the Deutsche Bank 2025 Healthcare Summit on Thursday, September 11, 2025, at 8:00 a.m. EDT. Members of management will discuss the Company’s business and financial results through August, which are consistent with its previously-issued full year 2025 forecast of approximately $1.75 adjusted diluted earnings per share (EPS). A simultaneous live audio webcast of Centene's participation in the summit on September…

DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS (a) On August 12, 2025, Director Thomas R. Greco notified Centene Corporation (the Company) of his resignation, including from his service on the Compensation and Talent Committee and the Governance Committee, effective August 22, 2025. Mr. Greco's resignation was due to increased professional responsibilities resulting from his recent appointment a…

DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS (b) On August 1, 2025, Director Wayne S. DeVeydt notified Centene Corporation (the Company) of his resignation, effective immediately. Mr. DeVeydt's resignation was not the result of any dispute or disagreement with the Company or the Company's Board of Directors (the Board) on any matter relating to the operations, policies or practices of the Comp…

REGULATION FD DISCLOSURE On May 6, 2025, members of Centene Corporation's (the Company's) senior management team will meet with investors. Consistent with the Company's guidance previously provided on April 25, 2025, the senior management team plans to reaffirm the Company's 2025 full year GAAP diluted earnings per share (EPS) guidance floor of greater than $6.19 and its full year adjusted diluted EPS guidance floor of greater than $7.25. Non-GAAP Financial Presentation The Company is providi…

REGULATION FD DISCLOSURE Centene Corporation will be presenting at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025, at 2:30 p.m. EDT. A simultaneous live audio webcast of the presentation on March 12 will be available at https://event.webcasts.com/starthere.jsp?ei=1711439&tp_key=abafa719df&tp_special=8. A webcast replay will be available following the presentation via the Company's website at www.centene.com, under the Investors section. During the presentat…

REGULATION FD DISCLOSURE On March 4, 2025, members of Centene Corporation's (the Company) senior management team will meet with investors. Consistent with the Company's guidance previously provided on February 4, 2025, the senior management team plans to reaffirm the Company's 2025 full year adjusted diluted earnings per share (EPS) guidance floor of greater than $7.25. Non-GAAP Financial Presentation The Company is providing certain non-GAAP financial measures in this Form 8-K as the Company…

REGULATION FD DISCLOSURE On November 13, 2024, members of Centene Corporation's (the "Company") senior management team will meet with investors. Consistent with the Company's guidance previously provided on October 25, 2024, the senior management team plans to reaffirm the Company’s 2024 full year adjusted diluted earnings per share (EPS) guidance of greater than $6.80. The senior management team also plans to reiterate that the Company expects to grow adjusted diluted EPS in 2025 and beyond.…

DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS On November 8, 2024, Kenneth J. Fasola, President of Centene Corporation (the "Company"), informed the Company that he intends to retire from the Company on July 1, 2025. Between now and the end of 2024, Mr. Fasola will transition his current duties and thereafter serve as Strategic Advisor, reporting to Sarah M. London, the Company's Chief Executiv…

REGULATION FD DISCLOSURE The Centers for Medicare and Medicaid Services (CMS) issued 2025 Medicare Advantage Star Ratings on October 10, 2024. Based on the data, Centene Corporation has approximately 46% of its Medicare Advantage membership enrolled in plans rated 3.5 stars or higher – compared to approximately 23% in the prior year. This represents meaningful progress and is consistent with internal expectations despite higher than industry-anticipated cut point changes. Additionally, we are…

DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS On October 2, 2024, the Board appointed Thomas R. Greco to the Governance Committee and the Compensation and Talent Committee. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CENTENE CORPORATION Date: Octo…

DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS (b) On September 25, 2024, Director Lori J. Robinson notified Centene Corporation (the “Company”) of her decision not to stand for re-election when her term expires at the Company’s 2025 Annual Meeting. The Company greatly appreciates Director Robinson’s five years of service, leadership and contributions to the Board. SIGNATURE Pursuant to the requ…

REGULATION FD DISCLOSURE The Company will meet with investors on Tuesday, Sept. 17, 2024 and present at the Bank of America 2024 Global Healthcare Conference in London on Wednesday, Sept. 18, 2024, which will be webcast at https://bofa.veracast.com/webcasts/bofa/globalhealthcareuk2024/x1aRN0.cfm at 5:50 am EDT /10:50 am BST. In both instances, the Company expects to reaffirm the 2024 full year adjusted diluted earnings per share (EPS) guidance of greater than $6.80. Non-GAAP Financial Present…

REGULATION FD DISCLOSURE On September 10, 2024, members of Centene Corporation’s (the "Company") senior management team will meet with investors. Consistent with the Company’s guidance previously provided on September 4, 2024, the senior management team plans to: • reaffirm the Company’s 2024 full year adjusted diluted earnings per share (EPS) guidance of greater than $6.80; • reiterate the shift of 20 to 30 cents of adjusted diluted EPS from Q3 to Q4. Therefore, the Company projects Q3 adjus…

RESULTS OF OPERATIONS AND FINANCIAL CONDITION On July 22, 2024, the Centers for Medicare and Medicaid Services (CMS) published the final risk adjustment transfers for the 2023 benefit year, resulting in a final $0.0 billion receivable for Centene. As a result of the publication of the benefit year 2023 reports, the Company is providing information regarding Centene's estimated net risk adjustment payable as of March 31, 2024, as well as summarizing the second quarter and expected full year 20…

REGULATION FD DISCLOSURE The Company will be presenting at the Bernstein 40 th Annual Strategic Decisions Conference, which will be webcast at https://event.webcasts.com/starthere.jsp?ei=1668807&tp_key=5c9c1d110a&tp_special=8 at 8:00 a.m. Eastern Daylight Time on Friday, May 31, 2024, and will be meeting with investors thereafter. The Company expects to reaffirm the 2024 full year adjusted diluted earnings per share (EPS) guidance of greater than $6.80 and full year consolidated health benefi…

DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS (b) Consistent with his previously announced intention to retire in 2024 as disclosed in the 8-K dated May 22, 2023, James E. Murray has retired from the Company effective March 29, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersi…

REGULATION FD DISCLOSURE Centene Corporation will be presenting at the Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024, at 8:00 a.m. EDT. During the presentation, the Company expects to reaffirm its previously issued 2024 adjusted diluted earnings per share (EPS) annual guidance of greater than $6.70. A simultaneous live audio webcast of the presentation on March 12 will be available at: https://event.webcasts.com/starthere.jsp?ei=1659141&tp_key=18b8362d5e&tp_spec…

REGULATION FD DISCLOSURE The Centers for Medicare and Medicaid Services issued 2024 Medicare Advantage Star Ratings, published on the Medicare Plan Finder on October 13, 2023. Following an analysis of the newly released data, the Company finds the 2024 Medicare Advantage Star results consistent with its most recent publicly stated targets. Based on the data, approximately 73% of membership is associated with contracts showing year-over-year unrounded score improvement, and approximately 87% o…